Shockwave Reducer Demonstrates Significant Quality-of-Life Improvement in Refractory Angina Patients with or without Diabetes, According to Real-World REDUCER-I Data Published in European Heart Journal

Dec 01, 2025 22:11 CST Updated 22:11

Johnson & Johnson

Medical Device R&D and Manufacturer

Johnson & Johnson in the journal "European Heart Journal》Release about itsAngina Stent---Shockwave ReducerTreatmentClinical data of patients with refractory angina pectoris often combined with diabetes mellitus (DM)EDUCER-1). Research showsShockwave ReducerAble toSignificantly improve the quality of life for patients.

REDUCER-1 is aReal-world observational study evaluating the severity of angina and quality of life in patients with and without diabetes after CSR implantation.Differences in quality improvement. Across 25 centers in Europe,Enrollment371 patients.Among them, 175 cases were combined with diabetes (DM group), and 196 cases were not combined with diabetes (non-DM group).

Specific Research Results

No significant differences were observed in baseline demographic characteristics between the DM group and the non-DM group; both groups were predominantly male (77.7% in the DM group vs. 79.6% in the non-DM group), with mean ages of 69.5±8.2 years (DM group) and 68.7±10.7 years (non-DM group). The majority of patients in both groups had a history of PCI (74.9% in the DM group vs. 73.0% in the non-DM group), and the proportions of CCS III/IV patients were similar (73.1% in the DM group vs. 68.4% in the non-DM group).
At 12 months post-operation, the incidence of MACE was similar between the two groups (DM group 8.9% vs. non-DM group 6.3%; p=0.4), with myocardial infarction being the main component in both groups (DM group 6.6% vs. non-DM group 4.7%).
Compared with baseline, all SAQ subscale scores improved significantly at 12 months in both groups, with a greater improvement in the SAQ quality of life scale observed in the non-DM group.
At 12 months, the CCS grade distribution was similar between the two groups (p=0.55), with the proportion of patients still at CCS III/IV decreasing to 19.5% in the DM group and 16.1% in the non-DM group. In the DM group, 71.0% of patients showed an improvement of ≥1 CCS grade at 12 months, comparable to 68.0% in the non-DM group (p=0.66).

Conclusion

In the REDUCER-I study, regardless of whether diabetes was present or not, both groups of patients showed similar and significant improvement in angina symptoms within 12 months after CS Reducer treatment, with a low incidence of MACE. Although diabetic patients typically have a poorer prognosis after PCI, this disadvantage was not observed after CS Reducer implantation, suggesting that...Shockwave ReducerIt has potential application value in such populations.

Neovasc Reducer

Neovasc ReducerIt is a small, balloon-expandable dumbbell-shaped stent that can narrow the coronary sinus, thereby allowing blood...Redistributed to ischemic myocardium.

Neovasc ReducerIncluding the delivery system and stent.

Neovasc ReducerThe stent is made from a stainless steel tube through laser cutting. The stent is designed in a dumbbell shape, narrow in the middle (3mm in diameter) and wide at both ends (13mm).

The shape of the distal balloon of the delivery system is consistent with the stent, and there are three radiopaque markers on the balloon, located at both ends and the middle of the balloon respectively.

Shockwave Medical

ShockWave MedicalAs part of Johnson & Johnson Medical, it aims to transform the treatment of calcified cardiovascular diseases.ShockWave MedicalThe goal is to establish a new standard for medical device treatment of cardiovascular calcification diseases through its differentiated and proprietary localized delivery of ultrasound for the treatment of calcified plaques, which they callIntravascular Lithotripsy（“IVL”）。